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Summary
Background: Most randomised controlled trials (RCT)
for acute coronary syndrome (ACS) exclude patients
with significant comorbidities. This may lead to mis-
conceptions regarding applicable treatment modalities
and hospital outcomes. The objective of the present
analysis was to assess the importance of major comor-
bidities in patients admitted with ACS.
Methods and results:We used the Charlson comor-
bidity Index (CCI) to evaluate the impact of chronic co-
morbidities in 19496 patients included in the AMIS
Plus registry following admission for ACS to 63 Swiss
hospitals between 2002 and 2008. Among the studied
population, 3881 (19.9%) had at least one comorbidity
which would exclude them from most RCT for ACS.
When compared to patients with a CCI score of 0, those
with higher CCI scores were older, more frequently fe-
males, and had higher rates of hypertension, dyslipid-
aemia and obesity. They were less often treated with
guideline-recommended drugs and eligible patients un-
derwent acute reperfusion therapy less frequently. The
CCI was associated with an increased rate of in-hospi-
tal mortality (3.0%, 5.6%, 8.1% and 13.7% respectively
for a CCI score of 0, 1, 2, and 3 or more, p <0.001), and
remained a powerful predictor of hospital mortality by
multivariate analysis. For 3323 patients with long
term follow-up, mortality 1 year after discharge was
similarly correlated with the CCI (1.6%, 2.7%, 8.4%,
and 16.0% respectively for a CCI score of 0, 1, 2, and 3
or more, p <0.001).
Conclusions: Comorbidities have a major impact on
clinical presentation, management and outcome of pa-
tients admitted to hospital for ACS. This should be
taken into account when transposing results obtained
from RCT into the “real world”.
Introduction
Current management of acute coronary syndrome
(ACS) is based on guidelines issued by major cardiology
societies, established on the basis of results obtained
from randomised controlled trials (RCT) [1–4]. How-
ever, a notable limitation of the applicability of the re-
sults obtained in RCT for ACS is that these studies ex-
clude many patients who are commonly encountered in
daily clinical practice, in particular patients with mul-
tiple comorbidities, whose treatment can prove to be
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challenging and whose outcome may markedly depend
on the comorbid conditions [5–9].
We used the opportunity offered by AMIS Plus
(acute myocardial infarction and unstable angina in
Switzerland), a large prospective multicentre registry
of patients admitted with ACS in Switzerland, to as-
sess the impact of comorbidities on clinical presenta-
tion, management and outcome of all patients who pre-
sented with ACS.
Methods
The AMIS Plus registry
The AMIS Plus registry is a nationwide prospective registry
of patients with ACS admitted to hospitals in Switzerland.
The registry was started in 1997 and patient inclusion has
been ongoing since. The structure and design of the registry
have been previously reported [10–12]. Briefly, at the time of
the present publication, 63 hospitals (listed below) participate
using paper or electronic data capture to collect information
on patients admitted for acute coronary syndrome. Data is
entered by dedicated research personnel or by junior physi-
cians. Definitions of the main parameters are available on-
line in pop-up menus, for use during data capture. Data
checks for completeness, consistency and plausibility are car-
ried out systematically at the central data center (Institute
of Social and Preventive Medicine, University of Zurich), and
queries are made to local investigators as needed. Since
March 2005, a subset of 49 hospitals has collected individual
follow-up information at 3 and 12 months from the patient,
their relatives or the referring physician.
The AMIS Plus project is supported by the Swiss Societies of
Cardiology, Internal Medicine, and Intensive Care Medicine
and is sponsored by unrestricted grants from the Swiss Heart
Foundation as well as a number of pharmaceutical and med-
ical device companies (listed above). The registry was ap-
proved by the regional Ethical Committees for clinical stud-
ies and the Swiss Board for Data Security. Furthermore, the
present study complies with the Declaration of Helsinki.
Charlson index of comorbidities
The Charlson comorbidity index (CCI) is a scoring system
that involves weighting factors on the basis of disease sever-
ity. The definitions used for each comorbid condition have
been described previously [13]. The system was originally de-
veloped as a prognostic indicator in patients admitted to a
general medical service with a variety of medical conditions,
and was then validated in several cohorts of patients [14–17].
Since 2002, the CCI was included in the AMIS Plus ques-
tionnaire.
Patients
The present analysis included all patients included in the
AMIS Plus registry from January 2002 to December 2008
with valid data on CCI.
Statistical analysis
Data are presented as numbers (percentages) of valid cases
for discrete variables and as means (standard deviation) or
medians for continuous variables. Group differences were
compared using chi square analysis of variance or the Stu-
dent t test, as appropriate. A probability value of p <0.05 was
considered significant.
A multivariate logistic regression model was used to de-
termine predictors of in-hospital mortality from the following
set of variables available at admission: age, sex, hyperten-
sion, dyslipidemia, smoking at time of admission, obesity, Kil-
lip class (class I as reference category), CCI (CCI score of 0 as
reference category), pre-hospital cardio-pulmonary resuscita-
tion, ST elevation and/or left bundle branch block (LBBB) on
admission ECG. Since diabetes is a component of the CCI, it
was not included in the regression model. However, in order
to determine the prognostic value of the CCI independently
from the impact of diabetes, we repeated the regression model
after excluding diabetes from the CCI and including it as an
independent variable.
SPSS (version 15.0, SPSS Inc., Chicago, IL) was used for
all statistical analyses.
Results
From the 20252 patients included in the AMIS Plus
registry during the study period, 19496 (96%) had
valid data on CCI and hospital outcome. Follow-up in-
formation was obtained from 4256 patients at 3 months
(96.0% of those who consented and were eligible) and
3323 patients at 12 months (96.8% of those who con-
sented and were eligible).
The prevalence of each comorbidity composing the
CCI, as well as the assigned weight of each condition,
are shown in table 1. The most common comorbidities
Cardiovascular Medicine 2010;13(5):155–161
Table 1
Prevalence of conditions composing the Charlson comorbidity index and their
assigned weight.
Comorbid condition Weight n % of
patients population
History of prior myocardial infarction 1 3554 18.2
Heart failure 1 765 3.9
Peripheral vascular disease 1 1056 5.4
Cerebrovascular disease 1 1165 6.0
Dementia 1 366 1.9
Chronic lung disease 1 1184 6.1
Connective tissue disease 1 185 0.9
Peptic ulcer disease 1 453 2.3
Diabetes without target organ damage 1 2964 15.2
Mild liver disease 1 154 0.8
Hemiplegia 2 167 0.9
Diabetes with target organ damage 2 747 3.8
Moderate to severe renal disease 2 1288 6.6
Malignant neoplasm 2 820 4.2
Leukaemia 2 55 0.3
Lymphoma 2 80 0.4
Moderate to severe liver disease 3 112 0.6
Metastatic solid tumour 6 175 0.9
Acquired immunodeficiency syndrome 6 33 0.2





CCI = 0 CCI = 1 CCI = 2 CCI ≥3 p
Patients, n (%) 10367 (53.2) 4447 (22.8) 2176 (11.2) 2506 (12.9)
Male gender (%) 7792 (75.2) 3196 (71.9) 1469 (67.5) 1693 (67.6) <0.001
Mean age (SD), years 61.9 (13) 67.2 (13) 71.5 (12) 74.3 (11) <0.001
Median 61 68 73 76
History of CAD (%)* 2259/10305 2423/4427 1265/2161 1682/2493 <0.001
(22.9) (54.7) (58.5) (67.5)
Diabetes mellitus (%)† 217/10005 1441/4308 846/2117 1254/2426 <0.001
(2.2)† (33.4) (40.0) (51.7)
Hypertension (%) 4820/9886 2907/4237 1587/2087 1916/2402 <0.001
(48.8) (68.6) (76.0) (79.8)
Dyslipidaemia (%) 4883/9277 2566/3945 1261/1911 1385/2158 <0.001
(52.6) (65.0) (66.0) (64.2)
Smoking (current) (%) 4374/9863 1383/4138 500/1998 526/2236 <0.001
(44.3) (33.4) (25.0) (23.5)
Obesity (BMI ≥30 kg/m
2
) (%) 1552/8911 834/3736 416/1817 463/2082 <0.001
(17.4) (22.3) (22.9) (22.2)
Pain to door median delay in min 222 225 240 285 0.110
interquartile range 25,75 111, 619 110, 643 120,713 125, 784
Clinical presentation
Typical symptoms (%) 5750/6446 2315/2640 1081/1305 1172/1538 <0.001
(89.2) (87.7) (82.8) (76.2)
Chest pain (%) 8508/10146 3495/4351 1665/2113 1742/2433 <0.001
(83.9) (80.3) (78.8) (71.6)
Dyspnoea (%) 1954/9741 1125/4198 711/2048 1120/2381 <0.001
(20.1) (26.8) (34.7) (47.0)
Killip class (n patients) 10313 4426 2164 2499 <0.001
Killip class I (%) 9014 3503 1507 1421
(87.4) (79.1) (69.6) (56.9)
Killip class II (%) 927 650 459 723
(9.0) (14.7) (21.2) (28.9)
Killip class III (%) 150 154 143 267
(1.5) (3.5) (6.6) (10.7)
Killip class IV (%) 222 119 55 88
(2.2) (2.7) (2.5) (3.5)
Out of hospital management
CPR (%) 303/10033 112/4321 43/2089 65/2423 0.078
(3.0) (2.6) (2.1) (2.7)
Cardioversion/defibrillation (%) 400/10035 129/4302 49/2089 54/2423 <0.001
(4.0) (3.0) (2.3) (2.2)
ECG at admission
Sinus rhythm (%) 9728/10325 3991/4414 1922/2161 2017/2480 <0.001
(94.2) (90.4) (88.9) (81.3)
Atrial fibrillation (%) 303/10325 238/4414 149/2161 299/2480 <0.001
(2.9) (5.4) (6.9) (12.1)
ST-elevation (%) 6174/10354 2143/4438 876/2170 909/2499 <0.001
(59.6) (48.3) (40.4) (36.4)
LBBB (%) 252/10350 232/4437 153/2169 252/2498 <0.001
(2.4) (5.2) (7.1) (10.1)
Q wave (%) 1044/10352 619/4437 260/2170 363/3499 <0.001
(10.1) (14.0) (12.0) (14.5)
CCI, Charlson comorbidity index; SD, standard deviation; CAD, coronary artery disease; BMI, body mass index; CPR, cardio-pulmonary
resuscitation; LBBB, left bundle branch block. *Includes angina pectoris, myocardial infarction, coronary artery bypass grafting or percu-
taneous coronary intervention. †In the AMIS Plus registry, patients diagnosed with diabetes before hospitalisation who remained un-
treated or had diabetes detected in hospital were considered as diabetics. For the CCI, a patient was considered as diabetic only if he
was taking oral antidiabetic medication or insulin before hospitalisation.
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reported were a history of a previous myocardial in-
farction, diabetes mellitus, moderate to severe renal
disease, chronic lung disease and cerebrovascular dis-
ease. More precisely, 3881 (19.9%) patients suffered
from at least one of the following comorbidities which
were considered as exclusion criteria in several major
RCT of ACS: cerebrovascular disease, hemiplegia, de-
mentia, connective tissue disease, peptic ulcer disease,
moderate to severe liver disease, moderate to severe
renal disease, solid malignant tumour, leukaemia, lym-
phoma, metastatic solid tumour and acquired immune
deficiency syndrome (AIDS) [18–20].
The overall mean CCI score was 1.01 ± 1.59. CCI
scores of 1, 2 and 3 or more applied respectively to
22.8%, 11.2% and 12.9% of the patient population,
while approximately half (53.2%) of the patient popu-
lation did not have any condition
included in the CCI, reported as a
CCI score of zero (table 2).
When considering baseline
characteristics, patients with
higher CCI scores were older, more
often female and had higher rates
of cardiovascular risk factors such
as hypertension, dyslipidaemia and
obesity. However, there was also a
lower proportion of active smokers
among these patients.
With regard to clinical parame-
ters, the patients with higher CCI
scores were admitted with higher
degrees of haemodynamic instabil-
ity (according to Killip class), while
their symptoms at admission time
were less typical than in patients
with lower rates of comorbidities.
Furthermore, the admission ECG
of patients with higher CCI scores
showed ST elevation less fre-
quently, whereas Q waves were
found more often.
Prescription of several guide-
line-recommended drugs (including
aspirin, clopidogrel, beta-blockers,
and statins) during the acute phase
and at discharge was significantly
less frequent for patients with
higher degrees of comorbidities, but
angiotensin converting enzyme in-
hibitors and angiotensin II receptor
blockers showed an opposite trend
(table 3).
Among the subgroup of pa-
tients admitted with ST elevation
myocardial infarction (STEMI) or
LBBB (n = 10824, 55.5%), reperfu-
sion either with primary percuta-
neous coronary intervention (PCI) or thrombolysis was
less frequently applied to patients with higher
comorbid conditions (table 4). Patients who did not un-
dergo reperfusion had a mean CCI score of 1.6, whereas
the mean CCI score of patients who underwent pri-
mary PCI and thrombolysis was 0.6 and 0.5, respec-
tively (p <0.001 across all 3 treatment modalities).
A higher CCI score was associated with an in-
creased rate in-hospital of major adverse cardiac and
cerebral events (MACCE), which include re-infarction,
cardiogenic shock, cerebrovascular events and to death
(table 5). Among the subset of patients with long-term
follow-up information, mortality remained higher after
3 and 12 months for patients with a higher CCI score.
Increased CCI scores were powerful predictors of
in-hospital mortality by multivariate analysis (table 6).
Cardiovascular Medicine 2010;13(5):155–161
Table 3
Drug therapy during acute phase (first 24 hours after admission) and at discharge.
Number of CCI = 0 CCI = 1 CCI = 2 CCI ≥ 3 p
patients/N (%)
Acute phase
Aspirin 9995/10338 4164/4433 2004/2169 2194/2492 <0.001
96.7% 93.9% 92.4% 88.0%
Clopidogrel 7830/10309 3113/4402 1291/2157 1302/2485 <0.001
76.0% 70.4% 59.9% 52.4%
Beta blocker 7446/10263 3123/4414 1490/2159 1566/2485 <0.001
72.6% 70.8% 69.0% 63.0%
Statin 8068/10278 3295/4412 1521/2160 1585/2479 <0.001
78.5% 74.7% 70.4% 63.9%
ACEI/ARB 4979/10250 2282/4407 1171/2158 1319/2490 <0.001
48.6% 51.8% 54.3% 53.0%
At discharge
Aspirin 9696/10021 3952/4181 1838/1992 1845/2155 <0.001
96.8% 94.5% 92.3% 85.6%
Clopidogrel 8344/10002 3220/4166 1307/1989 1210/2157 <0.001
83.4% 77.3% 65.7% 56.5%
Beta blocker 8505/9990 3532/4173 1651/1990 1686/2160 <0.001
85.1% 84.6% 83.0% 78.1%
Statin 9221/10002 3708/4173 1679/1992 1711/2155 <0.001
92.2% 88.9% 84.3% 79.4%
ACEI/ARB 7103/9969 3158/4170 1498/1990 1642/2156 <0.001
71.3% 75.7% 75.3% 76.2%
CCI: Charlson comorbidity index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin
receptor blocker.
Table 4
Reperfusion for patients with ST elevation myocardial infarction or left bundle branch block on admission.
CCI = 0 CCI = 1 CCI = 2 CCI ≥3 p
n patients 6354 2340 1005 1125
No reperfusion (%) 929 (14.6) 590 (25.2) 389 (38.7) 600 (53.3) <0.001
Thrombolysis (%) 636 (10.0) 188 (8.0) 63 (6.3) 43 (3.8) <0.001
Primary PCI (%) 4789 (75.4) 1562 (66.8) 553 (55.0) 482 (42.8) <0.001
CCI: Charlson comorbidity index; PCI: percutaneous coronary intervention.
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Other major independent predictors at admission were
age, Killip class, pre-hospital CPR and ST segment el-
evation on the first ECG. Furthermore, since diabetes
is one of the major components of the CCI and also a
major risk factor for ACS, we repeated the multivariate
analysis after exclusion of diabetes from the CCI score,
in order to determine if the prognostic value of the CCI
is merely a reflection of the impact of diabetes: CCI
scores of 1, 2 and 3 or more remained significant pre-
dictors of in-hospital mortality (odds ratio [OR] of 1.63
[95% confidence interval {CI} 1.17–2.28], 2.20 [95% CI
1.50–3.23] and 3.02 [95% CI 2.13–4.27], respectively).
This analysis also showed that diabetes was not a sig-
nificant predictor for in-hospital death (OR 1.28, 95%
CI 0.95–1.71).
Discussion
Previous studies have shown the
importance of comorbid conditions
in patients admitted with ACS.
However, these studies were either
focused on acute conditions only,
were monocentric or were based on
small populations [15, 21–23]. To
our knowledge, the present analy-
sis is the largest multicentric study
focusing on the importance of
chronic comorbid conditions among
patients admitted with ACS. Our
results confirm those from previous
studies, showing that chronic co-
morbidities are frequently encoun-
tered in patients admitted for ACS
in daily clinical practice. They also
show that patients with multiple
comorbid conditions differ signifi-
cantly from those with few or no co-
morbidities in terms of clinical
presentation, treatment and out-
come. Indeed, patients with a
higher CCI were typically older,
more often females and had higher
rates of hypertension, dyslipidaemia
and obesity. Furthermore, these pa-
tients were admitted more often
with non-ST elevation myocardial
infarction than patients with lower
CCI scores who presented more fre-
quently with STEMI. Interestingly,
active smoking was less often
encountered among patients with
higher CCI scores. This finding con-
curs with the suspected origin of
the “smoker’s paradox”, where
smokers have better outcomes than
non-smokers following acute myocardial infarction,
likely because of their younger age and lower risk pro-
file [24, 25]. Moreover, the fact that there was no posi-
tive effect of active smoking on survival after adjust-
ment for the CCI score in our multivariate analysis is
consistent with this hypothesis.
In our series, the presence of comorbidities was as-
sociated with a reduced use of most guideline-recom-
mended drugs as well as reperfusion therapies in eli-
gible patients. Fear of increased risk for adverse drug
and procedure related events among this population is
probably the main reason for this finding [7]. For in-
stance, the lower use of Aspirin, Clopidogrel and re-
perfusion therapies in patients with higher CCI scores
was possibly related to an increased haemorrhagic risk.
Nevertheless, the appropriateness of withholding such




CCI = 0 CCI = 1 CCI = 2 CCI ≥ 3 p
Patients (%) 10367 (53.2) 4447 (22.8) 2176 (11.2) 2506 (12.9)
In hospital outcome and hospital stay
Cardiogenic shock (%) 3.4 4.4 5.6 9.2 <0.001
Re-infarction (%) 0.8 1.6 2.4 2.2 <0.001
Cerebrovascular insult (%) 0.5 0.9 0.8 1.7 <0.001
In-hospital mortality (%) 3.0 5.6 8.1 13.7 <0.001
MACCE* (%) 4.0 7.1 10.0 16.1 <0.001
Median hospital stay (days) 5 6 7 8 <0.001
interquartile range 25,75 2, 8 2, 10 3, 12 4, 14
Out of hospital outcome
3 months mortality (n/N) % (18/2466) (8/909) (16/430) (29/451) <0.001
0.7 0.9 3.7 6.4
1 year mortality (n/N) % (31/1924) (19/699) (30/356) (55/344) <0.001
1.6 2.7 8.4 16.0
CCI: Charlson comorbidity index; MACCE: major adverse cardiac and cerebral events.
*Defined as re-infarction, cardiogenic shock, cerebrovascular event and death.
Table 6
Multivariate predictors of in-hospital mortality.
p OR 95 % CI for OR
CCI = 1 <0.05 1.51 1.07–2.14
CCI = 2 <0.001 2.62 1.79–3.83
CCI ≥ 3 <0.001 3.08 2.18–4.35
Age (1 year increase) <0.001 1.07 1.06–1.09
Killip Class II <0.001 2.49 1.84–3.37
Killip Class III <0.001 4.38 2.87–6.70
Killip Class IV <0.001 15.94 10.26–24.75
Hypertension <0.05 0.72 0.54–0.94
Prehospital CPR <0.001 4.7 2.90–7.44
OR: odds ratio; CI: confidence interval; CCI: Charlson comorbidity index; CPR: cardio-pulmonary
resuscitation; LBBB: left bundle branch block.
155-161 Fassa 073.qxp:Layout 1 29.4.2010 9:37 Uhr Seite 159
ORIGINAL ARTICLE
160
based guidelines are not available for these clinical si-
tuations. Furthermore, higher CCI scores were asso-
ciated with an increased risk of in-hospital mortality
and MACCE as well as mortality at follow-up. While
this poorer prognosis may be related to some extent to
the comorbidities themselves, underuse of guideline re-
commended therapies forACS, whether justified or not,
may also have contributed to this finding.
As several chronic diseases impact on the manage-
ment and outcome of patients suffering from a given
disease, and thus increase the background “noise” of
events, RCT usually have strict criteria which exclude
many patients with significant comorbidities in order
to increase the likelihood of identifying a significant
difference between the selected treatment arms [7].
The drawback of this, however, is that RCT only partly
reflect daily clinical practice, due to patients’ selection
and untoward bias. Therefore, results from RCT can be
difficult to apply in a “real world” setting since the pa-
tient population encountered may have been excluded
from these trials. In other words, guidelines mainly es-
tablished on the basis of RCT may be difficult to apply
as demonstrated in our study. Another important
caveat may concern registries. Indeed, adjusting for
baseline characteristics is increasingly used in numer-
ous registries when embarking upon comparisons be-
tween different sub-groups [26–29]. However, without
proper assessment of comorbidities, such adjustment
may be of only limited value. Our data support the con-
tention that all registries should account for a broad
spectrum of comorbid conditions, to allow identification
of confounding factors encountered in daily clinical
practice.
Limitations
The Charlson index was designed over 20 years ago,
and although it has become the most widely used in-
strument to quantify chronic comorbidities for patients
admitted to hospital for an acute major complaint, it
was not designed specifically for patients with ACS. It
gives a high score to certain items that have now be-
come rare in Switzerland, such as AIDS, while other
problems, such as conditions associated with increased
haemorrhagic or thrombotic risk, human immunodefi-
ciency virus status or transplant recipient on immuno-
suppressant drugs, might be of greater interest at the
present time.
The post-discharge follow-up was only available for
a subset of patients, and the numbers are still small, in
particular for the 12 month follow-up point. Larger
numbers will be required to confirm the long-term
prognostic value of the CCI score at admission for ACS
patients.
Conclusions
Chronic comorbidities have a major impact on clinical
presentation, management and outcome of patients ad-
mitted withACS. The overall comorbidity burden is in-
dependently associated with higher rates of in-hospi-
tal mortality. The excess mortality appears to persist
at 3 and 12 months follow-up.
Despite being among the most difficult patients to
manage, the sub-group of those with comorbid condi-
tions is poorly described in current literature and
guidelines, and many of them are excluded from stan-
dard RCT.
In order to improve management of these patients,
further efforts are warranted to include these patients
in RCTs onACS and also take into account the effect of
comorbidities in major registries.
Participating centres
The following hospitals participated in the AMIS Plus reg-
istry from 2002 to 2008 (in alphabetical order): Kantonsspital,
Aarau; Bezirksspital, Affoltern am Albis; Kantonsspital, Alt-
dorf; Kantonales Spital, Altstätten; Kantonsspital, Baden;
Kantonsspital, Basel; Beau-Site Klinik, Bern; Inselspital,
Bern; Spital Tiefenau, Bern; Spitalzentrum, Biel; Oberwal-
liser Kreisspital, Brig-Glis; Spital, Bülach; Regionalspital,
Einsiedeln; Regionalspital Emmental, Burgdorf; Kreuzspital,
Chur; Spital, Davos Platz; Spital, Dornach; Kantonales Spi-
tal, Flawil; Kantonsspital, Frauenfeld; Hôpital cantonal, Fri-
bourg; Spital, Frutigen; Hôpitaux universitaires, Genève;
Kantonsspital, Glarus; Spital, Grenchen; Kantonales Spital,
Herisau; Spital, Interlaken; Hôpital, La Chaux-de-Fonds;
Regionalsspital, Lachen; Regionalspital, Langnau im Em-
mental; GZF Regionalspital, Laufenburg; Cardiocentro Ti-
cino, Lugano; Kantonsspital, Luzern; Kreisspital, Männedorf;
Ospedale regionale, Mendrisio; Hôpital de la Tour, Meyrin;
Hôpital du Jura bernois, Moutier; Regionales Spital Zentrum,
Münsingen; Kantonsspital, Münsterlingen; Kreisspital für
das Freiamt, Muri; Group. Hosp. Ouest lémanique, Nyon;
Kantonsspital, Olten; GZF Regionalspital, Rheinfelden; Kan-
tonales Spital, Rorschach; Spital Oberengadin, Samedan;
Kantonsspital Obwalden, Sarnen; Kantonsspital, Schaff-
hausen; Spital Limmattal, Schlieren; Spital, Schwyz; Ospidal
d’Engiadina Bassa, Scuol; Bürgerspital, Solothurn; Kanton-
sspital, St. Gallen; Spital, Sursee; Spital, Thun; Spital, Uster;
Schwerpunktspital Zimmerberg-Horgen, Wädenswil; Kan-
tonales Spital, Walenstadt; GZO Spital, Wetzikon; Kanton-
sspital, Winterthur; Kantonales Spital Wolhusen, Wolhlusen;
Spital, Zofingen; Spital, Zollikerberg; Universitätsspital,
Zürich; Stadtspital Triemli, Zürich; Stadtspital Waid, Zürich.
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